Skip to main content
Home

Main navigation

  • Company
    • Company profile
    • Leadership team
    • Scientific Advisory Board
    • Board of Directors
  • R&D Programs
    • Pipeline overview
    • DIACC1010
    • DIACC2010/DIACC2020
    • DIACC3010
  • Partnering
  • Media
    • Media hub
    • All press releases
    • All events
    • Media center
  • Careers
  • Contact
  • Search
  • en
  • fr
Diaccurate key achievements

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA

Spaceadventure

Exploring new territories of oncology and immunology in search of therapeutic approaches able to save lives

VERY SERIOUS ABOUT INCURABLE DISEASES

Very serious about incurable diseases

Pipeline

Breaking the impasse with “sole-in-class" drug candidates

Latest news

Diaccurate welcomes to its Board of Directors Prof. Karine Lacombe, internationally renowned infectious disease specialist and Dr. Catherine George, expert in early drug development

June 24, 2022

Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer

February 8, 2022

Diaccurate Acquires Clinical Stage Sole-in-Class Targeted Cancer Therapy from Merck KGaA, Darmstadt, Germany

September 8, 2021
See all press releases

Upcoming events

See all upcoming events

Location

Headquarters: 104 Bd de Sébastopol, 75003 Paris

Lab: 60 avenue André Roussin, 13016 Marseille

  33 (0)1 78 96 41 70

Stay in touch

Subscribe to our newsletter

Contact us

Follow us

   

Footer

  • Legal info
  • Privacy notice
  • Cookies notice